← Back to Search

Cohort 4 for Skin Cancer

N/A
Waitlist Available
Led By Todd Tenenholz, MD, PhD
Research Sponsored by West Virginia University
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up up to 1 year
Awards & highlights

Study Summary

Oxygen has a critical role in the metabolism of tumors and normal tissues and is a key determinant of sensitivity of tissues to ionizing radiation. Knowledge of the relationship between the partial pressure of oxygen (pO2) and radiation sensitivity has been exploited in strategies to enhance oxygenation or to sensitize hypoxic cells to radiation. This study involves taking at least one measurement of the oxygen level in the patient's tumor before, during, and after breathing oxygen through a facemask. The goal of the measurements is to learn more about changes in tumor oxygen levels in response to breathing extra oxygen and standard treatments like chemotherapy and radiation therapy, so that in the future we have a better understanding of how to best use these treatments to improve their ability to fight cancer. By taking measurements of a variety of tumor types undergoing a variety of treatments, we will gain valuable information towards assessing our underlying hypothesis that repeated measurements of tissue oxygen levels can be used to optimize cancer therapy, especially radiation therapy, so that the therapy is applied in a way that maximizes the therapeutic ratio. All patients in this study will receive standard of care therapy for their cancer at the discretion of their treating physician(s).

Eligible Conditions
  • Skin Tumors
  • Skin Cancer

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~up to 1 year
This trial's timeline: 3 weeks for screening, Varies for treatment, and up to 1 year for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
To assess change in oxygenation of cutaneous tumors from hyperoxygenation therapy
Secondary outcome measures
To characterize temporal variations in oxygenation of cutaneous tumors over a course of local radiation therapy and/or systemic chemotherapy or immunotherapy
Other outcome measures
To compare different methods of oxygenation measurement

Trial Design

4Treatment groups
Experimental Treatment
Group I: Cohort 4Experimental Treatment2 Interventions
Patients who will receive systemic therapy alone (without radiation) for any tumor involving the skin.
Group II: Cohort 3Experimental Treatment2 Interventions
Patients who will receive palliative radiation (+/-concurrent systemic therapy) for any tumor involving the skin.
Group III: Cohort 2Experimental Treatment2 Interventions
Patients who will receive definitive radiation (+/- concurrent systemic therapy) for a primary malignancy of the skin
Group IV: Cohort 1Experimental Treatment2 Interventions
Patients who will receive definitive surgery for a primary malignancy of the skin.

Find a Location

Who is running the clinical trial?

West Virginia UniversityLead Sponsor
176 Previous Clinical Trials
60,314 Total Patients Enrolled
Todd Tenenholz, MD, PhDPrincipal InvestigatorWest Virginia University Cancer Institute

Frequently Asked Questions

~6 spots leftby Apr 2025